{"id":2982,"date":"2025-01-09T01:55:25","date_gmt":"2025-01-09T01:55:25","guid":{"rendered":"https:\/\/medical-article.com\/?p=2982"},"modified":"2025-01-09T01:55:25","modified_gmt":"2025-01-09T01:55:25","slug":"life-sciences-companies-falling-behind","status":"publish","type":"post","link":"https:\/\/medical-article.com\/?p=2982","title":{"rendered":"Life sciences companies falling behind?"},"content":{"rendered":"<p>That is what an <a href=\"https:\/\/www.pwc.com\/us\/en\/industries\/pharma-life-sciences\/pharmaceutical-industry-trends.html\">analysis from PwC finds<\/a>, at least with respect to stock market returns.<\/p>\n<p> Our PwC equal-weight index of 50 pharma companies analyzes the sector\u2019s total shareholder returns performance relative to the S&amp;P 500 Equal Weighted Index. From 2018 through November 2024, the PwC pharma index returned 7.6% to shareholders, compared with more than 15% for the S&amp;P 500.\u202fOver the last year, this dynamic became even more pronounced with the PwC pharma index returning 13.9% compared to 28.7% for the S&amp;P through November 2024. <\/p>\n<p>https:\/\/www.pwc.com\/us\/en\/industries\/pharma-life-sciences\/pharmaceutical-industry-trends.html<\/p>\n<p>Unsurprisingly, value growth is highly concentrated in just a few companies:<\/p>\n<p> \u2026since 2018, an increasingly limited set of companies have influenced positive returns in the pharmaceuticals sector. Within the S&amp;P 500, the so-called \u201cMagnificent 7\u201d accounted for 40% of the increase in value since 2018. In the pharma industry, this dynamic is even more stark with just two [leading GLP-1 manufacturers]\u2026accounting for nearly 60% of the increase in value growth among the 50 pharma companies analyzed by PwC.\u202f <\/p>\n<p>With the advent of the IRA and increasing pressure on price negotiation in many countries, will investors continue to fund life science innovators?  Let me know your thoughts.<\/p>","protected":false},"excerpt":{"rendered":"<p>That is what an analysis from PwC finds, at least with respect to stock market returns. Our PwC equal-weight index of 50 pharma companies analyzes the sector\u2019s total shareholder returns performance relative to the S&amp;P 500 Equal Weighted Index. From 2018 through November 2024, the PwC pharma index returned 7.6% to shareholders, compared with more&#8230;<\/p>\n","protected":false},"author":0,"featured_media":2983,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-2982","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles"],"_links":{"self":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/posts\/2982"}],"collection":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2982"}],"version-history":[{"count":0,"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/posts\/2982\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/media\/2983"}],"wp:attachment":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2982"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2982"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2982"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}